LICENSING OPPORTUNITY in Cancer Eradication, Killing and Metastasis Retardation from the NIH

LICENSING OPPORTUNITY in Cancer Eradication, Killing and Metastasis Retardation from the NIH

This webinar has already taken place. However, you can watch a recording of it by clicking on the screen shot just below.Originally aired on April 20th, 2016

 

One Million Solutions in Health™ has established a one-of-a-kind, new partnership with the United States’ National Institutes of Health Office of Technology Transfer (NIH-OTT) and the National Cancer Institute Technology Transfer Center (NCI-TTC) to increase awareness and understanding of NIH technologies by potential partners in the life science and healthcare industries.

THE GOAL OF THIS PARTNERSHIP IS TO INCREASE THE LICENSING AGREEMENTS AND COLLABORATIONS WITH THE NIH AND INDUSTRY.

This provides you with a front-row seat to hear about new technology and science from various scientists at the NIH.

Soon, this opportunity to learn directly from a number of NIH scientists, will ONLY be made available to members of our Technology Evaluation Consortium™ (TEC). But, for the next few months, this information is being shared beyond our current membership, to provide you and/or your organization with the opportunity to join the consortium.

This is also your opportunity to participate in our exclusive Signature Square™ process, where end-users rate and evaluate the technology, providing feedback directly to the scientist, to help effect and drive the NIH research Road Map for this technology. 

ERADICATE CANCER – UNIQUE STRATEGIES, SOLUTIONS AND PATENTS

This talk, entitled “Chemokine-based simple strategies to control immune responses and combat cancer” will cover the following areas:

– Use of chemokines to kill tumor cells by delivering toxins

– Inactivating immune cells by delivering oligonucleotides

– Retarding the growth and metastasis of CCR4-expressing malignancies

– Depleting Tregs and thereby shifting the balance towards anti-tumor immunity

– Inactivating the function of immune cells by delivering siRN

Photo Credit: 2013 ‘New Scientist’ Eureka Prize for Science Photography Highly Commended

“Chemokine-based simple strategies to control immune responses and combat cancer”

The focus of this presentation will be to present various patented chemokine-based strategies to control immune responses and eradicate and kill cancer, as well as retarding metastasis.

Cancer strategies often don’t cure patients, and patients often relapse. To illicit long-lasting, disease-free survival, current thinking suggests the need to induce immune responses against cancer.

To do this, a number of strategies can be utilized under the auspices of cancer immunotherapy. If you are searching for unique solutions for eradicating cancer, this presentation is for you.

Current member companies in the Technology Evaluation Consortium include organizations like Pfizer, AbbVie, Amgen and Allergan, along with many others. However, on a trial basis, we are allowing new industry participants, and other scientists, clinicians and investors in organizations around the world, to evaluate this technology and take part in this Signature Square evaluation.

THE GOAL OF THIS NIH and One Million Solutions in Health PARTNERSHIP IS TO INCREASE THE LICENSING AGREEMENTS AND COLLABORATIONS WITH THE NIH AND INDUSTRY.  

---

PANELISTS
	SPEAKER: Dr. Bira Arya Senior Investigator National Institute on Aging – IRP
	MODERATOR: Dawn Van Dam President & CEO One Million Solutions in Health™